Cancer Targeted Technology

Executive Summary

Cancer Targeted Technology (CTT) is a Seattle-based biotechnology company focused on developing small molecule theranostics for prostate cancer. Founded in 2008, CTT has pioneered a proprietary platform that combines diagnostic imaging and therapeutic capabilities into a single agent, enabling precise tumor targeting and real-time monitoring of treatment response. The company's lead candidates target PSMA, a well-validated biomarker overexpressed in prostate cancer cells, offering the potential for improved diagnostic accuracy and therapeutic efficacy compared to conventional approaches. With over 15 years of research and development, CTT has built a robust patent portfolio and accumulated preclinical and early clinical data supporting its technology. While still at a relatively early stage, the company's focused strategy and strong intellectual property position it to address significant unmet needs in prostate cancer management. The convergence of precision medicine and targeted radiopharmaceuticals positions CTT as a potential player in the growing theranostics market, which is gaining traction with recent regulatory approvals and increasing clinical adoption.

Upcoming Catalysts (preview)

• Q3 2026Initial Phase I/II clinical data for lead PSMA-targeted theranostic60% success
• Q4 2026Strategic partnership or licensing deal for manufacturing or commercialization40% success
• Q2 2026Grant or non-dilutive funding from government agencies (e.g., NIH, DoD)70% success